Speakers

Plenary speakers

The ubiquitin proteolytic system: from basic mechanisms through human diseases, and on to drug targeting

Aaron Ciechanover

Aaron Ciechanover

Aaron Ciechanover is a Distinguished Professor at the Technion – Israel Institute of Technology. He received his M.Sc. (1971) and M.D. (1973) from the Hebrew University in Jerusalem, and his Ph.D. from the Technion (1982). There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin Rose from Philadelphia, they discovered that tagging of protein substrates with ubiquitin targets them for degradation. Among the many prizes he received are the 2000 Albert Lasker Award, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose). Among many learned bodies, he is a member of the Israeli National Academies of Sciences and Humanities, and the National Academies of Sciences (NAS) and Medicine (NAM) of the USA.

Full circle after 40 years: plasmids to… neurobiology?

Stanley N. Cohen

Stanley N. Cohen

Dr. Stanley N. Cohen is the Kwoh-Ting Li Professor of Genetics and Professor of Medicine at Stanford University. Dr. Cohen and his colleague Dr. Herbert W. Boyer revolutionized the disciplines of biology and chemistry in 1973 with their discovery of methods to transplant and clone genes, and are the inventors on the basic patents underlying the field of genetic engineering. He is the author of more than 360 scientific publications and the recipient of numerous honors and awards, including the National Medal of Science, the National Medal of Technology, the Lasker Award for Basic Medical Research, the Wolf Prize in Medicine, and the Shaw Prize in Life Science and Medicine.

From supramolecular chemistry towards adaptive chemistry: bioorganic and biomedical aspects

Jean-Marie Lehn

Jean-Marie Lehn

Jean-Marie Lehn is presently Professor at the University of Strasbourg Institute for Advanced Study (USIAS). He shared the Nobel Prize in Chemistry in 1987 for his studies on the chemical basis of "molecular recognition" (i.e. the way in which a receptor molecule recognizes and selectively binds a substrate), which also plays a fundamental role in biological processes.

Over the years his work led him to the definition of a new field of chemistry, which he has proposed calling "supramolecular chemistry" as it deals with the complex entities formed by the association of two or more chemical species held together by non-covalent intermolecular forces, whereas molecular chemistry concerns the entities constructed from atoms linked by covalent bonds. Subsequently, the area developed into the chemistry of "self-organization" processes and more recently towards "adaptive chemistry", dynamic networks and complex systems.

Base editing: chemistry on a target nucleotide in the genome of living cells

David Liu

David Liu

David R. Liu is the Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT, Professor of Chemistry and Chemical Biology at Harvard University, and Howard Hughes Medical Institute Investigator. Dr. Liu has earned several university-wide distinctions, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship. He has published approximately 150 papers and has 50 issued patents. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society Pure Chemistry Award, the Arthur C. Cope Young Scholar Award, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. In 2016 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and in 2017 was named to the Nature’s 10 researchers in world and to the Foreign Policy Leading Global Thinkers. Professor Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. He is the scientific founder or co-founder of several biotechnology and therapeutics companies including Ensemble Therapeutics, Permeon Biologics, Editas Medicine, Pairwise Plants, and Beam Therapeutics.

Keynote speakers

Bugs as drugs: microbial ecosystem therapeutics to treat gut dysbiosis

Emma Allen-Vercoe

Emma Allen-Vercoe
Professor of Molecular and Cellular Biology, University of Guelph
Co-founder, NuBiyota
Guelph, Canada

Development of a recombinant Ebola virus vaccine (Adenovirus type 5 vector)

Helen Huihua Mao

Helen Huihua Mao
Co-Founder and Executive Vice-President, Quality Assurance and Regulatory Affairs
CanSino Biologics Inc
Tianjin,China

Body on a chip systems to improve drug development

Michael L. Shuler

Michael L. Shuler
Samuel B. Eckert Professor of Engineering
Cornell University
Ithaca, USA

Biorenewables: carbohydrates to commodity chemicals

Roger Sheldon

Roger Sheldon
Distinguished Professor (Emeritus) of Biocatalysis Engineering Delft University of Technology
Delft, Netherlands

Industry trends and future vision of biomanufacturing

Shou-Bai Chao

Shou-Bai Chao
Senior Vice President
AstraZeneca BioVentures
Shanghai City, China

CRISPR-Cas systems : from humble beginnings to today’s headlines

Sylvain Moineau

Sylvain Moineau
Canada Research Chair in Bacteriophages
Université Laval Québec, Canada

Marine biotechnology: an ocean of opportunities toward the blue bioeconomy

Wei Zhang

Wei Zhang
Professor of Bioprocessing and Marine Biotechnology
Director of the Centre for Marine Bioproducts Development
Flinders University
Adelaide, Australia

Invited speakers

Development of super microbial cell factories for consolidated bioprocessing through synthetic bioengineering

Akihiko Kondo

Akihiko Kondo
Team Leader, Cell Factory Research
RIKEN Center for Sustainable Resource Science
Kanagawa, Japan

Development of stem cell expanding molecules

Anne Marinier

Anne Marinier
Principal Investigator and Director of Medicinal Chemistry
Institute for Research in Immunology and Cancer, Université de Montréal
Montréal, Canada

Digital biomanufacturing will enable advanced theranostics

Bill Whitford

Bill Whitford
Strategic Solutions Leader
GE Healthcare
Logan, USA

Challenges and strategies for solutions with biomanufacture: from bulk commodities to value-added products

Fengwu Bai

Fengwu Bai
Distinguished Professor
Shanghai Jiao Tong University
Shangai, China

Changing the paradigms of drug delivery to the eye

Heather Sheardown

Heather Sheardown
Canada Research Chair in Ophthalmic Biomaterials and Drug Delivery Systems
McMaster University
Hamilton, Canada

CRISPR/Cas9 technology may be used to correct genes responsible for several monogenic hereditary diseases

Jacques Tremblay

Jacques Tremblay
Professor
Université de Laval
Québec, Canada

Targeting tumors with bispecific antibodies and drug conjugates

John Babcook

John Babcook
Senior Vice-President, Discovery and Research
Zymeworks
Vancouver, Canada

Algal biorefinery to treat wastewater resources: producing value-added products and reclaimed water in semiarid regions

José Osvaldo Beserra Carioca

José Osvaldo Beserra Carioca
Professor, Federal University of Ceara (UFC)
Associated Researcher, Parque Tecnologico do Ceará (PADETEC)
Fortaleza, Brazil

How hydroxynitrile lyases evolved from esterases

Romas Kazlauskas

Romas Kazlauskas
Professor and Director of Graduate Studies in Biochemistry, Molecular Biology, and Biophysics
University of Minnesota
Minneapolis, USA

Applications of functional metagenomics

Trevor C. Charles

Trevor C. Charles
Professor, Department of Biology
Director, Waterloo Centre for Microbial Research
University of Waterloo
Waterloo, Canada

Date modified: